L-carnitine and long-chain acylcarnitines are positively correlated with ambulatory blood pressure in humans: The SABPA study

Lipids

Volumn 48, Issue 1, 2013, Pages 63-73

  Mels, Catharina M C ^a   Schutte, Aletta E ^a   Erasmus, Elardus ^a   Huisman, Hugo W ^a   Schutte, Rudolph ^a   Fourie, Carla M T ^a   Kruger, Ruan ^a   Van Rooyen, Johannes M ^a   Smith, Wayne ^a   Malan, Nicolaas T ^a   Malan, Leoné ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

Oxidation; Ambulatory blood pressure; Ethnicity; Fatty acid metabolism; Heart lipid metabolism; l Carnitine; Lipid biochemistry; Long chain acylcarnitines; Nuclear receptors

Indexed keywords

ACYLCARNITINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CARNITINE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; LONG CHAIN ACYLCARNITINE; MEDIUM CHAIN ACYLCARNITINE; REACTIVE OXYGEN METABOLITE; SHORT CHAIN ACYLCARNITINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE MONITORING; BODY MASS; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; ETHNIC DIFFERENCE; HUMAN; MALE; MEAN ARTERIAL PRESSURE; NEGRO; OXIDATIVE STRESS; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CARNITINE; CROSS-SECTIONAL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; HYPERTENSION; MALE; MIDDLE AGED;

EID: 84872356625     PISSN: 00244201     EISSN: 15589307     Source Type: Journal    
DOI: 10.1007/s11745-012-3732-8     Document Type: Article

References (37)

1. Opie LH, Seedat YK (2005) Hypertension in sub-Saharan African populations. Circulation 112:3562-3568
2. Addo J, Smeeth L, Leon DA (2007) Hypertension in sub-saharan Africa: a systematic review. Hypertension 50:1012-1018
3. Mate A, Miguel-Carrasco J, Monserrat MT, Vázquez CM (2010) Systemic antioxidant properties of l-carnitine in two different models of arterial hypertension. J Physiol Biochem 66:127-136
4. Rauchová H, Dobesová Z, Drahota Z, Zicha J, Kunes J (1998) The effect of chronic l-carnitine treatment on blood pressure and plasma lipids in spontaneously hypertensive rats. Eur J Pharmacol 342:235-239
5. Gómez-Amores L, Mate A, Revilla E, Santa-María C, Vázquez CM (2006) Antioxidant activity of propionyl-l-carnitine in liver and heart of spontaneously hypertensive rats. Life Sci 78:1945-1952
6. Gómez-Amores L, Mate A, Miguel-Carrasco J, Jiménez L, Jos A, Cameán AM, Revilla E, Santa-María C, Vázquez CM (2007) l-carnitine attenuates oxidative stress in hypertensive rats. J Nutr Biochem 18:533-540
7. O'Brien D, Chunduri P, Iyer A, Brown L (2010) l-carnitine attenuates cardiac remodelling rather than vascular remodelling in deoxycorticosterone acetate-salt hypertensive rats. Basic Clin Pharmacol Toxicol 106:296-301
8. Ruggenenti P, Cattaneo D, Loriga G, Ledda F, Motterlini N, Gherardi G, Orisio S, Remuzzi G (2009) Ameliorating hypertension and insulin resistance in subjects at increased cardiovascular risk: effects of acetyl-l-carnitine therapy. Hypertension 54:567-574
9. Miguel-Carrasco J, Monserrat MT, Mate A, Vázquez CM (2010) Comparative effects of captopril and l-carnitine on blood pressure and antioxidant enzyme gene expression in the heart of spontaneously hypertensive rats. Eur J Pharmacol 632:65-72
10. Mate A, Miguel-Carrasco J, Vázquez CM (2010) The therapeutic prospects of using l-carnitine to manage hypertension-related organ damage. Drug Discov Today 15:484-492
11. Sharma S, Black SM (2009) Carnitine homeostasis, mitochondrial function and cardiovascular disease. Drug Discov Today Dis Mech 6:e31-e39
12. Barger PM, Kelly DP (2000) PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med 10:238-245
13. Hojo Y, Noma S, Ohki T, Nakajima H, Satoh Y (1997) Autonomic nervous system activity in essential hypertension: a comparison between dippers and non-dippers. J Hum Hypertens 11(10):665-671
14. International Society for the advancement of Kinanthropometry (ISAK) (2001) International standards for anthropometric assessment. National library of Australia, Adelaide
15. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S (2007) Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105-1187
16. Hannon WH, Whitley RJ, Davin B, Fernhoff P, Halonen T, Lavochkin M, Miller J, Ojodu J, Therrell BL (2007) Blood collection on filter paper for newborn screening programs; approved standard. Clin Lab Stand Inst 23(21):1-33
17. Hayashi I, Morishita Y, Imai K, Nakamura M, Nakachi K, Hayashi T (2007) High-throughput spectrophotometric assay of reactive oxygen species in serum. Mutat Res 631:55-61
18. Benzie IF, Strain JJ (1996) The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem 239:70-76
19. Chace DH, Hillman SL, Van Hove JL, Naylor EW (1997) Rapid diagnosis of MCAD deficiency: quantitative analysis of octanoylcarnitine and other acylcarnitines in newborn blood spots by tandem mass spectrometry. Clin Chem 43:2106-2113
20. Reuter SE, Evans AM, Chace DH, Fornasini G (2008) Determination of the reference range of endogenous plasma carnitines in healthy adults. Ann Clin Biochem 45:585-592
21. Nakamura T, Sugihara H, Kinoshita N, Ito K, Adachi Y, Hirasaki S, Matsuo A, Azuma A, Kodo N, Nakagawa M (1999) Serum carnitine concentrations in patients with idiopathic hypertrophic cardiomyopathy: relationship with impaired myocardial fatty acid metabolism. Clin Sci (Lond) 97:493-501
22. Nakamura T, Sugihara H, Kinoshita N, Yoneyama S, Azuma A, Nakagawa M (2000) Can serum carnitine levels distinguish hypertrophic cardiomyopathy from hypertensive hearts? Hypertension 36:215-219
23. Foster KA, O'Rourke B, Reibel DK (1985) Altered carnitine metabolism in spontaneously hypertensive rats. Am J Physiol 249:E183-E186
24. Rebouche CJ (2004) Kinetics, pharmacokinetics, and regulation of l-carnitine and acetyl-l-carnitine metabolism. Ann NY Acad Sci 1033:30-41
25. Flanagan JL, Simmons PA, Vehige J, Willcox MDP, Garrett Q (2010) Role of carnitine in disease. Nutr Metab 7:30-44
26. Vorster HH, Venter CS, Wissing MP, Margetts BM (2005) The nutrition and health transition in the North West Province of South Africa: a review of the THUSA (Transition and Health during Urbanisation of South Africans) study. Public Health Nutr 8:480-490
27. Vaz FM, Wanders RJA (2002) Carnitine biosynthesis in mammals. Biochem J 361:417-429
28. Rudman D, Sewell CW, Ansley JD (1977) Deficiency of carnitine in cachectic cirrhotic patients. J Clin Invest 60:716-723
29. Palombo JD, Borum PR, Jenkins RL, Bistrian BR (1989) Blood carnitine status after othotopic liver transplantation in patients with end-stage liver disease. Am J Clin Nutr 50:504-507
30. Kratz A, Ferraro M, Sluss PM, Lewandroski KB (2004) Laboratory reference values. N Engl J Med 351:1548-1563
31. Ringseis R, Eder K (2009) Influence of pharmacological PPARα activators on carnitine homeostasis in proliferating and non-proliferating species. Pharmocol Res 60:179-184
32. Poynter ME, Daynes RA (1998) Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappa B signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 273:32833-32841
33. Maeda T, Wakasawa T, Funabashi M, Fukushi A, Fujita M, Motojima K, Tamai I (2008) Regulation of Octn2 transporter (SLC22A5) by peroxisome proliferator activated receptor alpha. Biol Pharm Bull 31:1230-1236
34. Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, Shimane M, Sai Y, Tsuji A (1998) Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 273:20378-20382
35. Grube M, Ameling S, Noutsias M, Köck K, Triebel I, Bonitz K, Meissner K, Jedlitschky G, Herda LR, Reinthaler M, Rohde M, Hoffmann W, Kühl U, Schultheiss HP, Völker U, Felix SB, Klingel K, Kandolf R, Kroemer HK (2011) Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy. Am J Pathol 178:2547-2559
36. Shah SH, Hauser ER, Bain JR, Muehlbauer MJ, Haynes C, Stevens RD, Wenner BR, Dowdy ZE, Granger CB, Ginsburg GS, Newgard CB, Kraus WE (2009) High heritability of metabolomic profiles in families burdened with premature cardiovascular disease. Mol Syst Biol 5:1-7
37. Mogensen CE (2002) Microalbuminuria in perspectives. In: Friedman EA, L'Esperance FA (eds) Diabetic renal-retinal syndrome: pathogenesis and management update. Kluwer, London